Elanco/$ELAN
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Elanco
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, poultry, and swine production.
- Ticker
- $ELAN
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 9,650
- Headquarters
- Indianapolis, United States
- Website
- www.elanco.com
Elanco Metrics
BasicAdvanced
$12B
-
-$0.41
1.68
-
Price and volume
Market cap
$12B
Beta
1.68
52-week high
$27.98
52-week low
$19.40
Average daily volume
5.2M
Financial strength
Current ratio
2.05
Quick ratio
0.908
Long term debt to equity
0.631
Total debt to equity
0.643
Interest coverage (TTM)
1.25%
Profitability
EBITDA (TTM)
1,007
Gross margin (TTM)
55.36%
Net profit margin (TTM)
-3.96%
Operating margin (TTM)
6.77%
Effective tax rate (TTM)
-19.88%
Revenue per employee (TTM)
$520,000
Management effectiveness
Return on assets (TTM)
1.56%
Return on equity (TTM)
-2.98%
Valuation
Price to revenue (TTM)
2.304
Price to book
1.76
Price to tangible book (TTM)
-7.95
Price to free cash flow (TTM)
30.522
Free cash flow yield (TTM)
3.28%
Free cash flow per share (TTM)
0.761
Growth
Revenue change (TTM)
11.95%
Earnings per share change (TTM)
-146.35%
3-year revenue growth (CAGR)
5.10%
3-year earnings per share growth (CAGR)
20.73%
What the Analysts think about Elanco
Analyst ratings (Buy, Hold, Sell) for Elanco stock.
Analyst projections of the future price of Elanco stock.
Bulls say / Bears say
Elanco delivered 8% organic constant-currency revenue growth in Q2 and raised its 2026 revenue, adjusted EBITDA and EPS outlook. That points to stronger near-term earnings expectations. (Elanco)
Zenrelia reached blockbuster status, while Credelio Quattro expanded to more than half of US veterinary clinics and gained share. These launches are already winning adoption, rather than relying only on pipeline promises. (Elanco)
Both US and international Pet Health revenue grew 9% on an organic constant-currency basis in the first half of 2026. International Zenrelia gains and Quattro launches in Australia, Canada and Japan give Elanco room to extend that momentum. (Elanco)
Net leverage was still 3.1x adjusted EBITDA at June 2026, with net debt of $3.159 billion; Q2 reported net interest expense rose $11 million year on year to $59 million. Debt servicing may absorb cash and limit flexibility even as Elanco works to reduce leverage. (U.S. Securities and Exchange Commission)
Befrena demand was more than twice expectations, but Elanco said supply would not be unconstrained until early 2027. The production bottleneck could delay sales from a promising launch. (The Motley Fool)
Elanco flags dependence on leading products and competition from cheaper generics as business risks. If erosion of established products outpaces new-product adoption, growth could fall short. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 15 Oct 2026.
Elanco Financial Performance
Revenues and expenses
Elanco Earnings Performance
Company profitability
Upcoming events
No upcoming events
Elanco News
AllArticlesVideos
Funds containing Elanco
AllUSDEURGBP
Fund name | Fund size | $ELAN weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap£SPX4 | $6.4B | 0.33% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.4B | 0.33% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.22% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | $3.2B | 0.22% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.